Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Longeveron Inc. is a clinical-stage biotechnology company focused on developing regenerative medicine therapies targeting aging-related and life-threatening conditions. The company operates within the biotechnology and life sciences industries, with a primary emphasis on cell-based therapies derived from mesenchymal stem cells (MSCs). Its core product candidate, Lomecel-B, is an investigational, allogeneic cellular therapy designed to address unmet medical needs in conditions associated with aging and chronic disease.
The company’s primary revenue activity to date has been research and development rather than commercial product sales, as it has not yet received regulatory approval for any therapies. Longeveron’s strategic positioning centers on leveraging standardized, scalable MSC manufacturing and clinical development expertise. The company was founded in 2014 and later became publicly traded through an initial public offering in 2021, listing its common stock on Nasdaq under the ticker LGVN.
Business Operations
Longeveron operates as a single reporting segment focused on research and development of cellular therapies. Its principal asset, Lomecel-B, is being evaluated in multiple clinical programs, including pediatric congenital heart disease, aging-related frailty, and neurodegenerative disorders. The company’s operations primarily involve clinical trial execution, regulatory engagement, and proprietary cell manufacturing processes.
The company conducts its manufacturing and research activities through internally controlled facilities and collaborates with academic and clinical research institutions to support its trials. Operations are primarily based in the United States, with additional clinical and operational activity in international jurisdictions. As of publicly available filings, the company does not report commercial-stage subsidiaries generating independent revenue streams.
Strategic Position & Investments
Longeveron’s strategy is centered on advancing Lomecel-B through late-stage clinical development and pursuing regulatory pathways that may allow for accelerated approval in high-unmet-need indications. Growth initiatives include expanding clinical indications for its MSC platform and strengthening its intellectual property portfolio related to cell therapy manufacturing and application.
The company has not disclosed a broad acquisition strategy and has instead focused on internal development and selective collaborations. Its investment priorities remain concentrated on clinical trials, regulatory readiness, and scaling manufacturing capabilities. The company is also exploring emerging applications of regenerative medicine in age-related and inflammatory conditions. Data inconclusive based on available public sources regarding material equity investments in external portfolio companies.
Geographic Footprint
Longeveron is headquartered in the United States, with its principal executive offices and operational facilities located in Florida. The company maintains a presence in North America as its primary market for clinical development and regulatory activity.
Internationally, Longeveron has conducted or supported clinical activities in the Caribbean, including operations in The Bahamas, and continues to evaluate opportunities for broader global clinical and regulatory engagement. Its geographic footprint remains focused on regions with established clinical research infrastructure rather than commercial distribution.
Leadership & Governance
Longeveron was founded by physician-scientists with expertise in regenerative medicine, and its leadership team reflects a focus on clinical development, regulatory strategy, and translational science. The company emphasizes disciplined clinical execution and long-term value creation through scientific validation.
Key members of the leadership team include:
- Wa’el Hashad, M.D. – Chief Executive Officer
- Joshua M. Hare, M.D. – Founder and Chief Science Officer
- Barry E. Butler – Chief Financial Officer
- Ana E. Rodriguez, M.D., Ph.D. – Chief Medical Officer
The board and executive leadership collectively guide the company’s strategic vision of developing scalable, evidence-based regenerative therapies addressing significant unmet medical needs.